Biostax (BTAX) 10-K/A 16 May 16 2015 FY Annual report (amended) Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Mar. 21, 2016	Jun. 30, 2015
Document And Entity Information
Entity Registrant Name	Immune Therapeutics, Inc.
Entity Central Index Key	1,559,356
Document Type	10-K/A
Document Period End Date	Dec. 31, 2015
Amendment Flag	true
Amendment Description	Immune Therapeutics, Inc (the “Immune Therapeutics”, “The Company”, “we”, “us”, “our”) is filing this Amendment No. 1 (Amendment) to its Annual Report on Form 10-K for the year ended December 31, 2015 (Original Form 10-K) filed with the Securities and Exchange Commission (SEC) on March 30, 2016 (Original Filing Date) to restate and revise the Company’s previously issued audited consolidated financial statements and related financial information for the year ended December 31, 2015 included in its Original Form 10-K. This Amendment is to correct misallocation of costs arising from the impairment of certain intellectual property in 2015 to Non-controlling Interest as reported on the consolidated balance sheet at December 31, 2015. Approximately $5.2 million of expense was recorded by the Company in 2015 for the impairment of certain intangible assets. Approximately $2.1 million of that expense should have been allocated to Non-controlling Interest instead of being applied to Accumulated Deficit.
Current Fiscal Year End Date	--12-31
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 11,367,906
Entity Common Stock, Shares Outstanding		200,449,342
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,015

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current Assets:
Cash and cash equivalents	$ 23,149	$ 191,987
Accounts receivable	$ 16,197
Prepaids and other current assets		$ 30,000
Total current assets	$ 39,346	221,987
Fixed Assets:
Computer equipment, net of accumulated depreciation of $6,331 and $3,778 respectively	$ 1,682	4,235
Intangible Assets:
Patents and licenses, net of amortization of $1,793,911 and $1,201,678, respectively		5,818,585
Deposits	$ 200	10,183
Total assets	41,228	6,054,990
Current Liabilities:
Accounts payable	1,924,672	2,077,194
Accrued liabilities	1,281,039	1,111,839
Current portion of notes payable	2,793,701	186,067
Total current liabilities	$ 5,999,412	3,375,100
Non-current liabilities:
Notes payable, less current portion		327,458
Total non-current liabilities		327,458
Total liabilities	$ 5,999,412	$ 3,702,558
Commitments and Contingencies (Note 10)
Stockholders’ Equity/(Deficit):
Common stock - par value $0.0001; 500,000,000 shares authorized; 174,850,047 and 134,417,210 shares issued and outstanding respectively	$ 17,485	$ 13,442
Additional paid in capital	343,434,786	337,985,787
Stock issuances due	1,140,303	847,279
Prepaid services	(660,417)	(3,553,186)
Accumulated deficit	(349,861,173)	(333,547,377)
Equity/(Deficit) attributable to common shareholders	(3,857,732)	1,745,945
Non-controlling interest	(2,100,452)	606,487
Total stockholders’ equity/ (deficit)	(5,958,184)	2,352,432
Total liabilities and stockholders' equity/(deficit)	$ 41,228	$ 6,054,990

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Accumulated depreciation	$ 6,331	$ 3,778
Amortization	$ 1,793,911	$ 1,201,678
Common Stock, Par Value	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	500,000,000	500,000,000
Common Stock, Shares Issued	174,850,047	134,417,210
Common Stock, Shares Outstanding	174,850,047	134,417,210

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Revenues, net	$ 16,197
Operating expenses:
Selling, general and administrative	2,734,414	$ 4,072,277
Research and development expense	977,203	2,413,286
Stock issued for services general and administrative	$ 6,240,143	19,116,075
Stock issued for services research and development		5,126,250
Warrant valuation	$ 46,189	1,748,576
Depreciation and amortization expense	594,785	2,879,311
Impairment of intangible assets	5,226,352	9,908,477
Total operating expenses	15,819,086	45,264,252
Loss from operations	(15,802,889)	(45,264,252)
Other expense:
Interest expense	(270,989)	$ (388,221)
Impairment of investment	$ (32,000)
Foreign exchange loss		$ (783)
Loss on settlement of debt	$ (843,573)	(4,284,957)
Total other expense	(1,146,562)	(4,673,961)
Net loss	(16,949,451)	(49,938,213)
Net loss attributable to non-controlling interest	(2,706,939)	(1,684,996)
Net loss attributable to common shareholders	$ (14,242,512)	$ (48,253,217)
Basic and diluted loss per share attributed to common shareholders	$ (0.09)	$ (0.49)
Weighted average number of shares outstanding	153,247,023	98,508,458

Consolidated Statements of Stoc

Consolidated Statements of Stockholders’ Equity/ (Deficit) - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Stock To Be Issued [Member]	Prepaid Service [Member]	Accumulated Deficit [Member]	Non-controlling Interest [Member]	Total
Balance at Dec. 31, 2013	$ 7,416	$ 308,180,119	$ 4,893,499	$ (13,447,109)	$ (283,002,678)		$ 16,631,247
Balance, shares at Dec. 31, 2013	74,161,639
Issuance of common stock for prepaid services	$ 1,718	11,275,282	787,501	(12,962,001)			(897,500)
Issuance of common stock for prepaid services, shares	17,178,294
Return of common stock for charitable donation	$ (10)	(749,990)					(750,000)
Return of common stock for charitable donation, shares	(100,000)
Amortization of prepaid services				22,855,925			22,855,925
Issuance of common stock for patents and license fees	$ 160	467,840					468,000
Issuance of common stock for patents and license fees, shares	1,600,000
Issuance of common stock for legal settlement	$ 65	448,435					448,500
Issuance of common stock for legal settlement, shares	650,000
Issuance of common stock to employees and consultants	$ 633	3,176,424	(1,028,157)				2,148,900
Issuance of common stock to employees and consultants, shares	6,329,000
Issuance of common stock in exchange for debt	$ 2,404	8,250,396	(1,150,000)				7,102,800
Issuance of common stock in exchange for debt, shares	24,037,450
Issuance of common stock for loan expenses and interest	$ 67	527,183	(224,800)				$ 302,450
Issuance of common stock for loan expenses and interest, shares	670,000						670,000
Issuance of common stock for cash and exercise of warrants	$ 989	4,661,522	(2,430,764)				$ 2,231,747
Issuance of common stock for cash and exercise of warrants, shares	9,890,827
Issuance and modification of common stock warrants		1,748,576					$ 1,748,576
Non-controlling interest in Cytocom, Inc. (Note 2)					$ (2,291,483)	$ 2,291,483
Net loss					(48,253,217)	(1,684,996)	$ (49,938,213)
Balance at Dec. 31, 2014	$ 13,442	337,985,787	847,279	(3,553,185)	(333,547,378)	606,487	2,352,432
Balance, shares at Dec. 31, 2014	134,417,210
Issuance of common stock for prepaid services	$ 1,667	2,730,708	535,000	(1,436,000)			1,831,376
Issuance of common stock for prepaid services, shares	16,672,504
Amortization of prepaid services				$ 4,328,768			4,328,768
Issuance of common stock for legal settlement	$ 100	79,900					80,000
Issuance of common stock for legal settlement, shares	1,000,000
Issuance of common stock in exchange for debt	$ 1,406	1,954,971	(257,000)				1,699,377
Issuance of common stock in exchange for debt, shares	14,058,833
Issuance of common stock for loan expenses and interest	$ 6	15,619					$ 15,625
Issuance of common stock for loan expenses and interest, shares	62,500						62,500
Issuance of common stock for cash and exercise of warrants	$ 824	589,651	$ 15,025				$ 605,500
Issuance of common stock for cash and exercise of warrants, shares	8,239,000
Issuance and modification of common stock warrants		46,189					46,189
Issuance of common stock for investment	$ 40	$ 31,960					32,000
Issuance of common stock for investment, shares	400,000
Net loss					(14,242,512)	(2,706,939)	(16,949,451)
Balance at Dec. 31, 2015	$ 17,485	$ 343,434,786	$ 1,140,303	$ (660,417)	$ (347,789,890)	$ (2,100,452)	$ (5,958,184)
Balance, shares at Dec. 31, 2015	174,850,047

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss including non-controlling interest	$ (16,949,451)	$ (49,938,213)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation	2,552	2,485
Amortization	592,233	2,876,826
Stock issued for services	$ 1,911,375	1,251,401
Stock issued for legal settlement		448,500
Stock issued for patents and license fees		468,000
Amortization of stock issued for prepaid services	$ 4,328,768	22,891,924
Impairment of intangible assets	5,226,352	9,908,477
Impairment of investments	32,000	0
Debt discount		25,000
Loss on settlement of debt and accounts payable	843,573	4,248,957
Stock warrant expense	$ 46,189	1,748,576
Stock issued for donation		(750,000)
Stock issued for loan expenses and interest	$ 15,625	$ 302,450
Changes in operating assets and liabilities:
Accounts receivable	(16,197)
Prepaid expenses and other current assets	39,983	$ 246,342
Accrued liabilities	194,201	630,662
Accounts payable	900,484	1,795,518
Net cash used in operating activities	$ (2,832,313)	(3,843,095)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of licenses		(57,340)
Purchase of computer equipment		(1,113)
Net cash provided by/ (used in) investing activities		(58,453)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of common stock and exercise of warrants	$ 605,500	2,231,747
Proceeds from notes payable	$ 2,057,975	1,623,525
Payments made on patent liability		(118,333)
Repayment of notes payable		(50,000)
Net cash provided by financing activities	$ 2,663,475	3,686,939
Decrease in cash	(168,838)	(214,609)
Cash and cash equivalents, beginning of year	191,987	406,596
Cash and cash equivalents, end of year	23,149	191,987
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	20,500	4,538
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Conversion of debt and accrued interest to common stock	0	2,159,248
Shares issued for accounts payable and accrued liabilities	855,804	580,404
Non-controlling interest	635,565	2,105,062
Settlement of note payable by issuance of new note payable	50,000	0
Notes payable for expenses paid by lender	$ 46,933	$ 0

Organization and Description of

Organization and Description of Business	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Organization and Description of Business	1. Organization and Description of Business Immune Therapeutics, Inc. (the “Company,” “we,” or “our”) was initially incorporated in Florida on December 2, 1993 as Resort Clubs International, Inc. (“Resort Clubs”). It was formed to manage and market golf course properties in resort markets throughout the United States. Galliano International Ltd. (“Galliano”) was incorporated in Delaware on May 27, 1998 and began trading in November 1999 through the filing of a 15C-211. On November 10, 2004, Galliano merged with Resort Clubs. Resort Clubs was the surviving corporation. On August 23, 2010, Resort Clubs changed its name to pH Environmental Inc. (“pH Environmental”). On April 23, 2012, pH Environmental completed a name change to TNI BioTech, Inc., and on April 24, 2012, we executed a share exchange agreement for the acquisition of all of the outstanding shares of TNI BioTech IP, Inc. On September 4, 2014, a majority of our shareholders approved an amendment to our Amended and Restated Articles of Incorporation, as amended, to change our name to Immune Therapeutics, Inc. We filed our name change amendment with the Secretary of State of Florida on October 27, 2014 changing our name to Immune Therapeutics, Inc. The Company currently has an office in Orlando, Florida. In July 2012, the Company’s focus turned to acquiring patents that would protect and advance the development of new uses of opioid-related immune- therapies, such as low dose naltrexone (“LDN”) and Methionine [Met5]-enkephalin (“MENK”). In October 2012, the Company formed TNI BioTech International, Ltd., a BVI company in Tortola, British Virgin Islands, which was set up to allow the Company to market and sell LDN in those countries outside the U.S. in which we have been able to obtain approval to sell the Company’s products. In August 2013, the Company formed its United Kingdom subsidiary, TNI BioTech, LTD (the “UK Subsidiary”). The UK Subsidiary received approval to be considered a micro, small or medium-sized enterprise (“SME”) with the European Medicines Agency (“EMA”) on August 21, 2013. The designation provides the UK Subsidiary with significant discounts when holding meetings or submitting filings to the EMA. On September 19, 2013, the UK Subsidiary submitted a pre-submission package to the EMA regarding Crohn’s Disease. The EMA granted the UK Subsidiary a meeting that took place on September 27, 2013. The UK Subsidiary is eligible to benefit from the provisions for administrative and financial assistance for SMEs set out in Regulation (EC) No 2049/2005. The Company will apply to obtain EMA benefits once funding becomes available. In December 2013, the Company formed a new subsidiary, Cytocom Inc., to focus on conducting LDN and MENK clinical trials in the United States. In December 2014, the Company completed the distribution of common stock of Cytocom Inc. to its shareholders. As part of the transaction, the Company retained exclusive rights to all international patents, in-country approvals, formulations, trademarks, manufacturing, marketing, sales, and distributions rights in emerging nations, including Africa, Central America, South America, Russia, India, China, Far East, and The Commonwealth of Independent States (former Soviet Union). The Company will continue to have access to existing clinical data as well as any new data generated by Cytocom Inc. during drug development. On December 8, 2014, the number of Cytocom Inc. shares of common stock that were issued to our shareholders totaled 113,242,522 shares. In connection with the transaction, Cytocom Inc. issued 140,100,000 shares of its common stock to the Company, which gave the Company a 55.3% stake in Cytocom Inc. on that date. The stake has since been reduced to 50.2% at December 31, 2015, by subsequent issuances of Cytocom common stock to shareholders. In March 2014, the Company incorporated Airmed Biopharma Limited, an Irish corporation with an address in Dublin, Ireland, and Airmed Holdings Limited, an Irish company domiciled in Bermuda. The Irish companies were set up to benefit from incentives granted by the Irish government for the establishment of pharmaceutical companies (many of the world’s leading pharmaceutical companies have located in Ireland), and so that the Company could take advantage of Ireland’s status as a member of the European Union and the European Economic Area. An Irish limited liability company enjoys a low corporate income tax rate of 12.5%, one of the lowest in the world. The Irish-domiciled company hopes to qualify for tax incentives for Irish holding/headquartered companies and to benefit from the network of double tax treaties that reduce withholding taxes. TNI BioTech International, Ltd. will manage our international distribution, using product that is manufactured in Ireland and elsewhere. We are focused on the development and commercialization of therapeutic treatments for cancer, HIV/AIDS and autoimmune diseases and immune disorders by combating these severe and fatal diseases through the stimulation and/or regulation of the body’s immune system. Our growth strategy includes the near-term commercialization of our existing immunotherapies targeting cancer, Crohn’s disease and/or HIV/AIDS. Going Concern The Company has incurred significant net losses since inception and has relied on its ability to fund its operations through private equity financings. Management expects operating losses and negative cash flows to continue at more significant levels in the future. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval, and commercialization of its product candidate and the achievement of a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private or public debt or equity offerings, and may seek additional capital through arrangements with strategic partners or from other sources. Based on the Company’s operating plan, existing working capital at December 31, 2015 was not sufficient to meet the cash requirements to fund planned operations through December 31, 2016 without additional sources of cash. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business. The Company has experienced a net loss from operations of $16,949,451 and has used cash and cash equivalents for operations in the amount of $2,832,213 during the year ended December 31, 2015, resulting in a stockholder’s deficit of $5,958,184.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with United States (U.S.) generally accepted accounting principles (U.S. GAAP) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented. The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue for the year ended December 31, 2014. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act. Revenue Recognition Revenue from product sales is recognized upon passage of title and risk of loss to customers. Provisions for discounts, rebates and sales incentives to customers, and returns and other adjustments are provided for in the period the related sales are recorded. Historical data are not yet readily available and reliable for use in estimating the amount of the reduction in gross sales. Revenue from the launch of a new product, from an improved version of an existing product, or for shipments in excess of a customer’s normal requirements will be recorded when the conditions noted above are met. In those situations, management will record a returns reserve for such revenue, if necessary. If in future the Company participates in selling arrangements that include multiple deliverables (e.g., instruments, reagents, procedures, and service agreements), under these arrangements, the Company will recognize revenue upon delivery of the product or performance of the service and will allocate the revenue based on the relative selling price of each deliverable, which will be based primarily on vendor specific objective evidence. Revenue from license of product rights is recorded over the periods earned. In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers, which provides a single comprehensive model for accounting for revenue from contracts with customers and will supersede most existing revenue recognition guidance. Early adoption is not permitted. The standard becomes effective for the Company in the first quarter of 2017. The Company is currently evaluating the effect, if any, that the standard will have on its consolidated financial statements and related disclosures. Use of Estimates The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates. Cash, Cash Equivalents, and Short-Term Investments The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $250,000. At December 31, 2015, the Company has no cash balances in excess of insured limits. Segment and Geographic Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and does not segment the business for internal reporting or decision making. Fair Value of Financial Instruments In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “ Financial Instruments” Fair Value Measurements The ASC Topic 820, Fair Value Measurement, Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to five years. Maintenance and repairs are charged against expense as incurred. Depreciation expense from continuing operations for the years ended December 31, 2015 and December 31, 2014 was $2,552 and $2,485, respectively. Intangible Assets Costs incurred to acquire and/or develop the Company’s product licenses and patents are capitalized and amortized by straight-line methods over estimated useful lives of ten to sixteen years. Intangible assets are stated at the lower of cost or estimated fair value. During the years ended December 31, 2015 and December 31, 2014, the Company capitalized $nil and $57,340 respectively, of such costs incurred for the Company’s acquisition of licenses for the patents. (See Note 10). Amortization expense for the years ended December 31, 2015 and December 31, 2014 was $592,233 and $2,876,826, respectively. Impairment of Long-Lived Assets The Company evaluates long-lived assets for impairment whenever events or change in circumstances indicate that the carrying amount of an asset may not be recoverable as prescribed by ASC Topic 360-10-05, “ Property, Plant and Equipment Research and Development Costs Research and development costs are charged to expense as incurred and are typically comprised of salaries and benefits, pre-clinical studies, clinical trial activities, drug development and manufacturing, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf and third-party service fees, including clinical research organizations and investigative sites. Costs for certain development activities, such as clinical trials are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as operating expenses. Income Taxes The Company follows ASC Topic 740, Income Taxes, The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. At the date of adoption, and as of December 31, 2015, and 2014, the Company does not have a liability for unrecognized tax uncertainties. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of December 31, 2015, and 2014, the Company has not accrued any interest or penalties related to uncertain tax positions. Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors, including employee stock options, based on estimated fair values equaling either the market value of the shares issued or the value of consideration received, whichever is more readily determinable. The majority of the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair value of the Company’s common stock at the date of the agreement. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 505-50, “ Equity-Based Payments to Non-Employees Non-controlling Interest In accordance with ASC Topic 810, Consolidation Net Loss per Share Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. Dilutive common stock equivalents are comprised of common stock purchase warrants outstanding. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. A calculation of basic and diluted net loss per share follows: For the year ended December 31, 2015 2014 Historical net loss per share: Numerator Net loss $ (16,949,451 ) $ (49,938,213 ) Non-controlling interest (2,706,939 ) (1,684,996 ) Net loss attributed to Common stockholders $ (14,242,512 ) $ (48,253,217 ) Denominator Weighted-average common shares outstanding— Denominator for basic and diluted net loss per share 153,247,023 98,508,458 Basic and diluted net loss per share attributed to common stockholders $ (0.09 ) $ (0.49 ) The Company’s potential dilutive securities which include stock and warrants have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average Common stock outstanding used to calculate both basic and diluted net loss per share is the same. The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as the effect of including such securities would be antidilutive: Year Ended December 31, 2015 2014 Common Stock Purchase Warrants 9,131,500 9,296,750 Recent Accounting Standards During the year ended December 31, 2015 and through March 30, 2016, there were several new accounting pronouncements issued by the Financial Accounting Standards Board. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial statements. The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue and did not have such amount as of December 31, 2015, our last fiscal year. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2015
Fixed Assets:
Property and Equipment	3. Property and Equipment December 31, 2015 2014 Property and equipment: Computer equipment $ 8,013 $ 8,013 Less accumulated depreciation (6,331 ) (3,778 ) Property and equipment, net $ 1,682 $ 4,235 The Company utilizes the straight-line method for depreciation, using three to five-year depreciable asset lives. Depreciation expense was not material for all periods presented.

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
Accrued Liabilities	4. Accrued Liabilities Accrued expenses and other liabilities consist of the following: December 31, 2015 2014 Retainer for legal services $ - $ 60,000 Accrued payroll to officers and others 758,342 762,633 Accrued interest - notes payable 236,671 1,808 Estimated legal settlement 282,136 278,681 Other accrued liabilities 323 6,933 State payroll taxes 3,567 1,784 Total accrued expenses and other liabilities $ 1,281,039 $ 1,111,839

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Notes Payable	5. Notes Payable Notes payable consist of the following: December 31, 2015 December 31, 2014 Promissory note issued July 29, 2014 to Ira Gaines. The note matures on January 27, 2015 and earns interest at a rate of 18% per annum. The Company was unable to repay the note at maturity and the note is in default, although no demand for repayment has been made by the lender. $ 100,000 $ 100,000 Promissory notes issued between November 26, 2014 and September 30, 2015, to raise up to $2,000,000 in debt. Lenders earn interest at a rate of 10% per annum, plus a pro-rata share of two percent of the Company’s gross receipts for sales of IRT-103-LDN in perpetuity. Notes will be repaid in 36 monthly installments of principal and interest commencing no later than October 15, 2015. Notes aggregating $711,500 were in default at December 31, 2015, as the Company was unable to pay installments on those notes on their due dates. No demands for repayment have been made by the lenders. Subsequent to December 31, 2015, $380,500 of these notes and their accompanying interest were converted into 5,389,409 shares of Immune Therapeutics common stock. 711,500 406,525 Promissory note issued October 17, 2014 to Roger Bozarth. The note matures on October 17, 2015 and earns interest at a rate of 2% per annum. The Company was unable to repay the note at maturity and the note is in default, although no demand for repayment has been made by the lender. Subsequent to December 31, 2015, this note and the accompanying interest was converted into 89,639 shares of Immune Therapeutics common stock. 7,000 7,000 Promissory notes issued between May 1, 2015 and September 30, 2015, and maturing between June 14, 2015 and December 31, 2015. Lenders on loans aggregating $506,433 earn interest at rates between 10% and 18% per annum. On loans aggregating $98,500, interest is payable in a fixed amount not tied to a specific interest rate. Notes aggregating $669,933 were in default at December 31, 2015, as the Company was unable to repay those notes on their due dates. No demands for repayment have been made by the lenders. Subsequent to December 31, 2015, $135,000 of these notes and their accompanying interest were converted into 2,870,377 shares of Immune Therapeutics common stock. 669,933 - Promissory note issued January 26, 2015 to Robert J. Dailey. The note is senior to, and has priority in right of payment over, all indebtedness of the Company. The note earns interest at a rate of 2% per annum and was due on July 30, 2015. The Company was unable to repay the note at maturity and the note is in default, although no demand for repayment has been made by the lender. 200,000 - Promissory notes issued by Cytocom Inc. between April 29, 2015 and December 31, 2015. Lenders earn interest at rates between 5% and 10% per annum. These notes mature on September 30, 2016. 800,000 - Promissory notes issued in December 2015. Lenders earn interest at a rate of 10% per month. Notes are repayable on March 9, 2016. The Company was unable to repay the note at maturity and the note is in default. The Company is obligated to pay late-payment penalties totaling $6,667 per day. 130,000 - Promissory note issued November 24, 2015 as settlement of amounts owing to a law firm. The Lender earns interest at the rate of 10% per annum. The note is repayable in full on December 1, 2016. 175,268 - Total 2,793,701 513,525 Less: Current Portion (2,793,701 ) (186,067 ) Long-Term debt, less current portion $ - $ 327,458 F-13 As of December 31, 2015, the Company had accrued $236,671 in unpaid interest, compared to $1,808 as of December 31, 2014. During the year ended December 31, 2015, 62,500 shares with a fair value of $15,625 were issued by the Company for interest expense under promissory notes (compared to 670,000 shares issued for interest and loan expenses with a fair value $302,450 in the year ended December 31, 2014).

Capital Structure - Common Stoc

Capital Structure - Common Stock and Common Stock Purchase Warrants	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Capital Structure - Common Stock and Common Stock Purchase Warrants	6. Capital Structure—Common Stock and Common Stock Purchase Warrants Each holder of common stock is entitled to vote on all matters and is entitled to one vote for each share held. No holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock or any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend. As of December 31, 2015 and 2014, the Company was authorized to issue 500,000,000 common shares at a par value of $0.0001 per share. As of December 31, 2015, the Company had 174,850,047 shares of common stock outstanding and 134,417,210 outstanding as of December 31, 2014. Stock Warrants In 2015, the Company issued 435,000 warrants, exercisable into one share of common stock of the Company for each warrant at prices between $0.07 and $0.50 per share. The warrants expire between Jan 2016 and Dec 2021. When the Company sells its stock to stockholders for cash, it periodically issues warrants to those stockholders to acquire additional stock at prices agreed at the date of the original sale. The Company incurs a cost for the rights attached to the warrants, which is calculated using the Black-Scholes Model. This expense is reported in the Condensed Consolidated Statements of Operations above as the Warrant valuation expense. During 2015, there were no modifications of the terms of any warrants issued by the Company. Following is a summary of outstanding stock warrants at December 31, 2015 and 2014 and activity during the years then ended: Number of Shares Exercise Price Weighted Average Price Warrants as of December 31, 2014 9,396,750 $ 0.14-15 $ 1.72 Issued 435,000 $ 0.07-0.50 $ 0.40 Expired (676,250 ) $ 1.50 $ 1.50 Exercised (24,000 ) $ 0.50 $ 0.50 Warrants as of December 31, 2015 9,131,500 $ 0.07-15.00 $ 1.47 Summary of outstanding warrants as of December 31, 2015: Expiration Date Number of Shares Exercise Price Remaining Life (years) Second Quarter 2016 37,500 $ 5.00 .50 Third Quarter 2016 525,000 $ 1.00-5.00 .75 Third Quarter 2017 1,500,000 $ 1.00 1.75 Fourth Quarter 2017 2,941,666 $ 1.00-9.00 2.00 First Quarter 2018 127,500 $ 15.00 2.25 Second Quarter 2018 33,334 $ 15.00 2.50 Third Quarter 2018 650,000 $ 1.00-1.50 2.75 Fourth Quarter 2018 1,197,500 $ 1.00-1.50 3.00 First Quarter 2019 1,024,000 $ 1.50 3.25 Second Quarter 2019 135,000 $ 0.07–0.23 3.50 Third Quarter 2019 260,000 $ 0.50 3.75 Fourth Quarter 2019 400,000 $ 0.14 4.00 Second Quarter 2020 300,000 $ 0.50 4.50

Stock Compensation

Stock Compensation	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Stock Compensation	7. Stock Compensation Shares Issued for Services During the years ended December 31, 2015 and 2014, the Company issued 16,672,504 and 17,178,294 shares of common stock respectively for consulting fees. The Company valued these shares based upon the fair value of the common stock at the dates of the agreements. The consulting fees are amortized over the contract periods which are typically between 12 and 24 months. The amortization of prepaid services totaled $4,328,768 and $22,855,925 for the years ended December 31, 2015 and 2014.

Income Taxes - Results of Opera

Income Taxes - Results of Operations	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes - Results of Operations	8. Income Taxes Results of Operations There was no income tax expense reflected in the results of operations for the years ended December 31, 2015 and 2014 because the Company incurred a net loss in both years. Deferred tax assets: 2015 2014 Net operating losses $ 22,611,000 $ 20,710,000 Stock based compensation 60,914,000 59,032,000 Amortization, depreciation, and impairment 6,765,000 4,786,000 Capitalization of start-up costs for tax purposes 1,854,000 1,854,000 Loss on debt conversion of debt 502,000 502,000 Total deferred tax assets 92,646,000 86,884,000 Valuation allowance (92,646,000 ) (86,884,000 ) Total deferred tax assets, net $ - $ - The Company has recognized no tax benefit for the losses generated for the periods through December 31, 2015. ASC Topic 740 requires that a valuation allowance be provided if it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company’s ability to realize the benefit of its deferred tax asset will depend on the generation of future taxable income. Because the Company has yet to recognize revenue, we believe that the full valuation allowance should be provided. Our effective tax rate for fiscal years 2015 and 2014 was 0%. Our tax rate can be affected by recurring items, such as tax rates in foreign jurisdictions and the relative amount of income we earn in jurisdictions. It may also be affected by discrete items that may occur in any given year, but are not consistent from year to year. As of December 31, 2015, we have estimated federal and state income tax net operating loss (“NOL”) carry-forwards of approximately $66,500,000, which will expire in 2032-2035. 2015 2014 Amount Percent Amount Percent Benefits for income tax at federal statutory rate $ 5,763,000 34 % $ 16,978,000 34 % Change in valuation allowance (5,762,000 ) (34 )% $ (16,973,000 ) (34 ) Permanent differences (1,000 ) - (5,000 ) - Non-deductible impairment of goodwill - - - - $ - - $ - - %

Licenses and Supply Agreements

Licenses and Supply Agreements	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Licenses and Supply Agreements	9. Licenses and Supply Agreements Patent and Subsidiary Acquisition The Company entered into a share exchange agreement on April 24, 2012 to acquire all of the outstanding shares of TNI BioTech IP, Inc. (“TNI IP”), a biotechnology firm incorporated in Florida and formed to acquire patents related to the treatment of cancer and HIV/AIDS and autoimmune diseases, using Met-enkephalin (“MENK”) and Naltrexone (“LDN”). The goal of TNI IP’s management was to enable mankind and civilization to combat fatal diseases by activating and mobilizing the body’s own immune system using TNI IP’s patented use of MENK. The first patents acquired by TNI IP were acquired from Dr. Nicholas P. Plotnikoff and Professor Fengping Shan in 2012. TNI IP was acquired in exchange for 20,250,000 shares of the Company’s common stock, of which 8,000,000 shares were issued to Dr. Plotnikoff for the acquisition of patents and the remaining 12,250,000 shares were issued to the founders of TNI IP in exchange for all of their right, title and interest in their TNI IP shares. The goodwill arising on the acquisition of TNI BioTech IP, Inc. was valued at $98,000,000 and license agreements arising from the acquisition of TNI IP were valued at $16,006,000. In connection with the share exchange, we entered into a Sale of Technology Agreement with Dr. Nicholas P. Plotnikoff on March 4, 2012, wherein Dr. Plotnikoff agreed to transfer and assign all of his rights, title and interest in: European Patent United Kingdom, Germany, France, Ireland EP 1401471 BI Methods for inducing sustained immune response; Russian Patent Russian Federation patent number 2313364; The Patent Office of the People’s Republic of China, Application No.: 200810165784.8 China Patent CN1015113407 A The Patent Office of the People’s Republic of China ISSN: 1006-2858 CN 21-1349/R; Patent Agencies Government of India Patent, Application number 1627/KOLNP/2003 number 220265 an Enkephalin Peptide Composition; and the US Patent Pending, US Patent Application 10/146.999 e. The Company received all the production formulations and technology designs from Dr. Plotnikoff necessary for the manufacturing, formulation, production and protocols of the MENK treatment of cancer and HIV/AIDS. As consideration for entering into the Sale of Technology Agreement, Dr. Plotnikoff received 8,000,000 shares of common stock, a royalty of a single-digit percentage on all sales of MENK and was granted the position of Non-Executive Chairman of the Board of Directors. At the time of the acquisition, the valuation of goodwill and other intangible assets were determined using the fair market price for the Company’s common stock, which were exchanged for shares of TNI IP. In the fourth quarter of 2012, the Company performed an annual valuation to determine whether any goodwill or intangible assets that had been acquired by the Company were impaired. The result of this valuation was that material impairments were identified. The Company recognized an impairment of the goodwill arising on the acquisition of TNI IP of $98,000,000. Patent License Agreements On August 13, 2012, the Company signed an exclusive License Agreement with Ms. Jacqueline Young (the “Young Agreement”) for the intellectual property developed by Dr. Bernard Bihari relating to treatments with opioid antagonists such as naltrexone and Met-enkephalin for a variety of diseases and conditions including malignant lymphoma, chronic lymphocytic leukemia, Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma, chronic herpes virus infections, chronic herpes viral infections such as chronic genital herpes caused by the herpes simplex virus Type 2 and chronic infections due to the Epstein-Barr virus and a treatment method for humans infected with HTLV-III (AIDS) virus, including patients clinically diagnosed as suffering from AIDS and those suffering from AIDS-related complex (ARC). The Bihari patents were acquired in exchange for 540,000 shares of the Company’s common stock with a fair market value of $972,000 and assumed liabilities of $400,000, which is payable to Ms. Young over a twenty-four month period in equal installments to reimburse her for the costs of a New York City office in accordance with the Young Agreement. The patent liability at December 31, 2013 totaled $118,333. The cost of the patent totaled $1,372,000. Additionally, the Company will pay the licensor a royalty payment of 1% of gross MENK sales and provide the licensor a position as non-executive chairman of the Company. The Young Agreement is valid for the life of the patents and expires on a country by country basis in each country where patent rights exist, upon the expiration of the last to expire patent in each country or in the event the patent in such country is held to be invalid and/or unenforceable (by a court or government body of competent jurisdiction) or admitted to be invalid or unenforceable. Additionally, we can cancel the Young Agreement upon 120 days’ written notice and shall pay all royalties and fees that have accrued under the Young Agreement. We have the exclusive rights to the intellectual property; however, Ms. Young retains a right to practice the patents licensed under the Young Agreement solely for noncommercial, academic research purposes. On December 24, 2012, the Company signed an agreement for the acquisition of patent rights (the “Smith Agreement”) for the intellectual property of Dr. Jill Smith and LDN Research Group, LLC (collectively, the “Licensor Parties”), whose members are Dr. Ian S. Zagon, Dr. Patricia J. McLaughlin and Moshe Rogosnitzky and orphan drug designation by the FDA to a novel late-stage drug, trademarked “LDN,” for the treatment of Pediatric Crohn’s disease. The patent covers methods and formulations for treatment of the inflammatory and ulcerative diseases of the bowel, using naltrexone in low doses as an opioid antagonist. These patents were acquired in exchange for 300,000 shares of our common stock with a fair market value of $2,715,000 and payment of $165,384 (consisting of a $100,000 initial license fee and payment of $65,384 of expenses), which totaled $2,880,384. The Smith Agreement requires the Company to (i) use commercially reasonable efforts to develop, commercialize, market and sell licensed products in a manner consistent with a business plan, (ii) expend a minimum amount of funds per annum to develop and commercialize licensed products as soon as practicable, (iii) obtain all requisite regulatory approvals needed to use or sell licensed products in the field of use, and (iv) make the first commercial sale of a licensed product by March of 2017. The Company is required to pay an annual license fee, an annual running royalty on net sales of each licensed product or a minimum royalty, whichever is greater, and a sublicense fee on payments received by the Company from sublicensees. The Company has an exclusive, worldwide license to make, have made, use, lease, import, offer for sale and sell licensed products and to use the method under the patent rights. The Smith Agreement will terminate on the expiration or abandonment of the last patent to expire or ten years after the sale of the first licensed product. The Company may terminate the Smith Agreement upon 90 days’ written notice, provided all sublicenses are terminated and all amounts due and owing are paid to the Licensor Parties. The Licensor Parties may terminate the agreement ten days’ after notice to the Company if the Company is ten days late in payment or there is a breach that remains uncured for ten days after written notice of such breach. The Company is also required to pay milestone payments after substantial achievement of certain milestone events for each licensed product including payment: upon initiation of each Phase III trial; upon positive completion of each Phase III clinical trial of the therapeutic use of an LDN compound in the field of use; when a New Drug Application (“NDA”) is accepted for review by the FDA; and when FDA approval to market the NDA is approved. The Company will issue shares upon reaching certain milestones including upon the first dosing of the first patient in a Phase III clinical trial for each licensed product, upon the first sale of each licensed product, and upon the achievement of a set dollar amount in cumulative sales for each licensed product covered by NDAs. As part of the Smith Agreement, the Company has the right to apply to the FDA for the transfer of the orphan drug status for the use of naltrexone for the treatment of pediatric Crohn’s disease and ulcerative colitis, the Investigation New Drug Application (“IND”), and the right to acquire the relevant clinical data set from Dr. Jill Smith. Dr. Jill Smith made arrangements to transfer the IND to the Company as well as the relevant clinical data set, and the FDA has acknowledged that the Company is now the sponsor for this IND. On September 24, 2014, the Company and the Licensor Parties jointly agreed to terminate the Smith Agreement, and in place thereof, have the Licensor Parties grant a similar license in their patent rights to Cytocom Inc. pursuant to a Patent License Agreement between the Licensor Parties, Cytocom Inc. and the Company with substantially similar terms as set forth in the Smith Agreement. Pursuant to this agreement, the Company issued 1,000,000 shares of its common stock valued at $270,000, upon execution to the Licensor Parties and the Company guaranteed the obligations of Cytocom Inc. to the Licensor Parties under the agreement. On January 18, 2013, the Company signed an exclusive licensing agreement with The Penn State Research Foundation to license all of the intellectual property developed by Dr. Ian S. Zagon, Dr. Patricia J. McLaughlin and Dr. Jill P. Smith for the treatment of cancer titled “Opioid Growth Factor and Cancer” and “Combination Therapy with Opioid Growth Factor and Taxanes for the Treatment of Cancer” (the “Foundation Agreement”). The Foundation Agreement requires the Company to: (a) use commercially reasonable efforts to develop, commercialize, market and sell licensed products in a manner consistent with a business plan; (b) expend a minimum amount of funds per annum to develop and commercialize licensed products as soon as practicable; (c) obtain all requisite regulatory approvals needed to use or sell licensed products in the field of use; and (d) make the first commercial sale of a licensed product by December 31, 2016. The Foundation Agreement provides that the Company must pay to the licensor an initial license fee, a license maintenance fee on each anniversary of the effective date of the Foundation Agreement, and an annual running royalty on net sales for each licensed product or a minimum royalty, whichever is greater. In addition, the Company must pay a sublicense fee on payments received by the Company from sublicensees. The Foundation Agreement also requires the Company to make payments upon the achievement of certain milestone events including: initiation of each Phase II trial; initiation of each Phase III trial; when the NDA is accepted for review by the FDA; and when FDA approval to market is approved. The Company must also issue shares upon certain milestones including upon the first dosing of the first patient in a Phase II clinical trial for each licensed product, upon the first dosing of the first patient in a Phase III clinical trial for each licensed product, upon the first sale of each licensed product, and upon the achievement of a set dollar amount of cumulative sales for each licensed product covered by NDAs. The Foundation Agreement terminates on the expiration or abandonment of the last patent to expire or become abandoned. The Company may terminate the Foundation Agreement at any time upon 60 days’ prior written notice and ceasing to make and sell all licensed products, the termination of all sublicenses and payment of all monies owed under the Foundation Agreement. The licensor may terminate the agreement 30 days after notice to the Company if the Company is 30 days late in payment or a breach that remains uncured for 45 days after written notice of such breach. In May of 2013, the Company executed a Patent License Agreement with Professor Fengping Shan (the “Shan Agreement”) pursuant to which it obtained exclusive rights to develop and commercialize the licensed technology. The licensed technology is the intellectual property developed and owned by Professor Shan (i) relating to the treatment of a variety of diseases and conditions with MENK including multiple forms of lymphoma and cancer and (ii) a treatment method for humans infected with the HLTV-III (AIDS) virus including AIDS and AIDS related complex (ARC). The licensed technology includes the methods and formulations for these treatments including all INDs, communications with regulatory agencies, patient data, and letters relating to these treatments. The licensed technology also includes certain patents developed by Professor Shan. Under the Shan Agreement, the Company must issue 500,000 shares to Professor Shan upon final transfer of the licenses, and reimburse Professor Shan for all out of pocket expenses in connection with the patents. The Company will pay Professor Shan a running royalty on gross sales subject to decreases if third party intellectual property is needed to complete such sale or product. The Shan Agreement lasts for the duration of each of the licensed patents however the Company may terminate the Shan Agreement on 120 days’ written notice to Professor Shan. On August 6, 2014, Professor Fengping Shan executed an Assignment pursuant to which he transferred to the Company his entire right, title and interest in and to the licensed patents under the Shan Agreement and CN 201210302259 Application of combination of low-dose naltrexone and methionine-enkephalin to preparation of anti-cancer drug for the consideration of 500,000 shares of common stock valued at $140,000.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies Malawi Treatment Facilities On July 14, 2012, GB Oncology and Imaging Group LTD (“GBOIG”) in partnership with the Company signed a letter of intent agreement to collaborate with the Government of Malawi to assist in expanding the treatment of cancer, HIV/AIDS and other infectious diseases. In December of 2014, the Government of Malawi completed an oncology clinic at the Queen Elizabeth Central Hospital in Blantyre, Malawi for the treatment of cancer and infectious diseases. In 2015, the Company submitted protocols seeking permission from the Pharmacy, Medicines and Poisons Board of Malawi (“PMPB”) to conduct two trials involving Lodonal™ in Malawi: a. The first protocol, submitted jointly with The Jack Brewer Foundation (“JBF Worldwide”), received PMPB approval on November 11, 2015. The protocol covers a 12-month trial for a “Single Visit Approach to Cervical Cancer Prevention.” The approach is designed to deliver a preventive and simple procedure that can be performed in a clinical setting without the use of a laboratory and to allow for immediate treatment of any precancerous lesions utilizing Wallach LL100 Cryosurgical systems. The protocol provides for 50% of the patient group to be put on Lodonal™ to determine if the drug lowers the number of opportunistic infections during the year, and if it can be shown that LDN increases CD4, CE8, NK and T cell count, which would show that the incidence rates of opportunistic infection could decrease with Lodonal™ and that Lodonal™ could be used as a prophylaxis to prevent substantial HIV-related morbidity in Malawi. The Company expects the final trial agreement with PMPB to be signed by the end of 2015. Lodonal™ pills have been produced in Nicaragua in anticipation of the trial. Shipments will commence once the trial is approved. b. The second protocol, which has not yet been approved, covers a trial using Lodonal™ for the treatment of cancer. The protocol is still under discussion with the PMPB, and the Company expects a final protocol to be submitted for approval by year end. The Company and GB will work with the government of Malawi to open and operate other clinics that provide treatments for HIV/AIDS, cancer and other infectious diseases. Under the letter of intent, the Company and GBOIG intend to provide HIV/AIDS treatment to 25,000 patients and hopefully expanding to 500,000 within 24 months. The Company shall contribute $1,000 in initial capital to the venture. The Company shall be allocated 50% of the net income from the venture. Either party may terminate the venture with 180 days’ notice to the other party prior to the one-year anniversary of the Agreement. After the one-year anniversary, the agreement may only be terminated with 180 days’ notice to the other party if the other party has breached the Agreement. GBOIG, a subsidiary of GB Energie LLC, is a Washington D.C. based minority woman-owned business managed by Dr. Gloria B. Herndon. Dr. Herndon is a former director of the Company. Dr. Herndon’s directorship with the Company ended September 4, 2014. Open an Oncology and Infectious Disease Center in Malawi at Queen Elizabeth Central Hospital On September 25, 2012, GBOIG, in partnership with the Company, signed an agreement with the Government of Malawi to open an outpatient clinic at Queen Elizabeth Central Hospital (in Malawi) for the treatment of cancer and infectious disease. The duration of the Agreement shall be for 25 years with an optional 10-year renewal to be indicated by the Government of Malawi at least three years prior to the expiration of the term. The Government of Malawi shall bear the upfront costs for the agreement of $2,500,000. Distribution Agreements in Nigeria Effective November 9, 2012, we signed an exclusive Distribution Agreement with G-Ex Technologies/St. Maris Pharma and GB Pharma Holdings, LLC for the Federal Republic of Nigeria. Under the terms of the Distribution Agreement, G-Ex Technologies/St. Maris Pharma and GB Pharma Holdings LLC will have exclusive marketing and distribution rights to IRT-103 LDN and IRT-104 LDN cream in Nigeria until the end of the term of the agreement on December 31, 2017. We will be responsible for the manufacture and supply of IRT-103 LDN and IRT-104 LDN cream. As part of the Distribution Agreement, G-Ex Technologies/St. Maris Pharma will provide us with a revolving letter of credit for the minimum purchase of 750,000 doses monthly of IRT-103 LDN or IRT-104 LDN cream priced at $1.00 per dose. There are no upfront fees. The Distribution Agreement calls for G-Ex Technologies/St. Maris Pharma and GB Pharma Holdings, LLC to purchase a minimum of 15,000,000 doses monthly within 24 months to maintain the exclusivity of the agreement. Once G-Ex Technologies/St. Maris Pharma and GB Pharma Holdings, LLC reach sales of 1,000,000 doses per day, we have agreed to joint venture a factory in the Federal Republic of Nigeria to meet local demands. G-Ex Technologies/St. Maris Pharma is a consortium of companies organized under the laws of the Republic of Nigeria operated by management, a consultant, general pharmaceutical, clinical pharmacy and marketing executives, each with over 25 years of industry experience and well versed in the changing dynamics of the prescription and over-the-counter drug international marketplace. G-Ex Technologies/St. Maris Pharma has been actively supported by medical practice professionals in business and academia who have been involved in the management of related drug therapies for many years. The parties have been unable to perform under the agreement because a certificate of free sale was not obtained by the Company until November of 2013, and no extension has been granted. In October 2013, the Company announced the signing of a Distribution Agreement with AHAR Pharma, a Nigerian company, to market Lodonal™, in Nigeria for the treatment of autoimmune diseases and cancer. AHAR intends to distribute Lodonal™ through a local distributor network, an Internet client base and directly to hospitals, pharmacists and doctors in Nigeria. The Company expects to implement the agreement in 2016. Under the agreement, the Company is obligated to provide delivery of an initial supply of between 1 million and 1.5 million doses of Lodonal™ product to cover AHAR Pharma’s first-year purchase commitment. In August 2015, the Company announced the signing of a letter of intent with GB Pharma/AHAR and Fidson Healthcare Plc., in terms of which Fidson will promote Lodonal TM TM Agreements with Hubei Qianjiang Pharmaceutical Company On October 18, 2012, the Company and Hubei Qianjiang Pharmaceutical Co., Ltd. (“Qianjiang Pharmaceutical”), signed a Venture Cooperation Agreement on New Drug Methionine Enkephalin (the “Venture Agreement”) pursuant to which Qianjiang Pharmaceutical acquired an exclusive license for the production of MENK in China. The Venture Agreement requires that Qianjiang Pharmaceutical conduct drug research and pilot testing for MENK, organize pre-clinical studies, and apply for clinical trials for MENK with the Chinese State Food and Drug Administration. Under the Venture Agreement, Qianjiang Pharmaceutical must open a co-administration account for the development of MENK in China. Qianjiang Pharmaceutical must pay the Company, upon the marketing of MENK products, a half-year amount equaling 6% of its gross sales from MENK of the preceding half year. The Company may cancel the Venture Agreement if Qianjiang Pharmaceutical does not pay expenses for a period exceeding six months or does not commence clinical trials within 12-months after receiving certain approvals. Qianjiang Pharmaceutical may cancel the Venture Agreement if the Company fails to perform its obligations for a period of six months or the failure to receive approval of clinical trials is due to the Company’s MENK technologies. The Venture Agreement was amended on February 24, 2013 to expand the clinical trials from pancreatic to both pancreatic and liver cancer and amended on March 6, 2014 to require Qianjiang Pharmaceutical to commence studies and clinical trials in China and place funds in the co-administration account. On August 6, 2014, the Company entered into a Supplementary Agreement on New Drug Methionine – Enkephalin Cooperation (the “Amendment”) with Qianjiang Pharmaceutical, amending the Venture Agreement, as amended. The Company and Qianjiang Pharmaceutical executed the Amendment to accelerate clinical trials in both the United States and China, and agreed to immediately initiate three month Good Laboratory Practice (“GLP”) Toxicology Studies (rat and dog) within 30 days of signing the Amendment. The Amendment requires that the GLP Toxicology Studies Trials are conducted in China in accordance with international standards and standards acceptable to the FDA and that the studies include the following: Exploratory Toxicology (nGLP) ● Dose range finding studies ● Different species and methods of administration ● Multiple dosing regimens ● Estimate the response vs. dose given Definitive Toxicology (GLP) ● Performed in collaboration with Calvert Laboratories (USA) and MPI/Medicillon (China) ● General toxicology studies ● Different species and methods of administration ● Immunogenicity study with NHPs Special Toxicology Studies (planned) Pursuant to the Amendment, Qianjiang Pharmaceutical has made certain funds available from the co-administrative account opened by Qianjiang Pharmaceutical under the Venture Agreement, in accordance with an approved budget and timeline set forth in the Amendment. A portion of these funds are expected to be used by Cytocom to run PK and Dosing trials for MENK in the United States in 2016. The Amendment requires Cytocom and Qianjiang Pharmaceutical to meet with the China State Food and Drug Administration to determine that PK and Dosing Trials completed in the United States will be acceptable. All developments and trials run by Cytocom in the U.S. or the European Union will be used for requesting registration approval in China. In February 2013, the Company signed a Strategic Framework Agreement for Cooperation with Qianjiang Pharmaceutical. Under the agreement, the parties will work together to further the development of new products and conduct research and development on the Company’s licensed patented technology. Specifically, the parties aim to co-invest to develop and market products focusing on HIV, cancer and related autoimmune system therapies, develop co-ventured manufacturing facilities in China, and develop co-ventured distribution of the developed products in China and Africa. The agreement does not have a definitive term, as each new agreement resulting from the cooperation will set forth the material terms, including, but not limited to, fees, duration and termination therein. Supervision and Inspection of Manufacturing in Nicaragua On April 23, 2013, the Company signed a Contract with ViPharma for the Supervision and Inspection of Manufacturing Processes as part of its negotiations for a contract for the manufacturing of LDN in a tablet, capsule and/or cream. The contract sets out the terms and conditions under which ViPharma will carry out the services of inspecting and supervising the manufacturing and packaging processes of LDN and ensure compliance with the FDA’s Current Good Manufacturing Practice regulations (“cGMP”) and the Company’s specifications. ViPharma will carry out its obligations in whatever Latin American country the Company ultimately decides to manufacture LDN. Under the contract, ViPharma has the exclusive rights to supervise and inspect all manufacturing processes of LDN in Latin America. The initial term of the agreement is ten years commencing in September 2013, with automatic five-year renewal terms provided neither party is in breach. The agreement may be terminated by (i) mutual agreement, (ii) in the event of a breach after a 45 day cure period or (iii) by either party upon provision of written notice at least 90 days before the end of the agreement, provided however that if the Company terminates the contract without cause it will be required to pay ViPharma a $10 million penalty. Operating Leases At December 31, 2015, the Company was a party to an agreement to lease office space in Orlando, Florida. Cash rental expense for the years ended December 31, 2015 and 2014 was $53,205 and $147,236 respectively. Legal Proceedings In February 2014, a claim was filed for breach of contract and unjust enrichment in the Circuit Court for Montgomery County, Maryland, E.J. Krause & Associates, Inc. v. TNI BioTech, Inc. In October 2014, a claim was filed for breach of contract and unjust enrichment in the United States District Court, Middle District of Florida, Orlando Division, QS Pharma, LLC v. TNI BioTech, Inc. n/k/a Immune Therapeutics, Inc In September 2015, a claim was filed for breach of contract, account stated, quantum meruit, and unjust enrichment in District Court for the Middle District of Florida, Epstein Becker & Green PC v. TNI Biotech, Immune Therapeutics, Inc. and Cytocom, Inc.,

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions	11. Related Party Transactions In 2012, Webfoot, Inc. provided a loan to the Company in the amount of $121,128. Webfoot, Inc. is owned by the son of Noreen Griffin, the Company’s Chief Executive Officer. On February 21, 2013, the Company entered into a formal loan agreement to evidence the amount owed by the Company. In the nine months ended September 30, 2014, the Company repaid $40,000 of the loan. On September 30, 2014, the remaining balance of $71,128 owed under the agreement, together with accrued and unpaid interest totaling $10,212, was converted into 813,404 shares of the Company’s common stock in full and final settlement of the loan. The loss on conversion was $162,681. In 2012, Noreen Griffin made payments totaling $30,000 on the Company’s behalf covering the costs of incorporation and merger-related expenses. On February 13, 2013, the Company entered into a formal loan agreement to evidence repayment of the amount owed on December 31, 2012. On September 30, 2014, the full balance of the loan, together with accrued and unpaid interest totaling $2,870, was converted into 328,701 shares of the Company’s common stock in full and final settlement of the loan. The loss on conversion was $65,740. In 2012, Griffin Enterprises, Inc. made payments totaling $46,000 on the Company’s behalf covering the cost of incorporation and merger-related expenses. Griffin Enterprises, Inc. is wholly owned by Noreen Griffin. On February 13, 2013, the Company entered into a formal loan agreement to evidence repayment of the amount owed on December 31, 2012. On September 30, 2014, the full balance of the loan, together with accrued and unpaid interest totaling $4,401, was converted into 504,009 shares of the Company’s common stock in full and final settlement of the loan. The loss on conversion was $100,802. On January 3, 2013, the Company formalized the terms under which Kelly O’Brien Wilson, the daughter-in-law of the Company’s Chief Executive Officer is employed. Ms. Wilson had been working with the Company in 2012 and her three-year employment agreement is effective as of December 1, 2012. The terms of the agreement define her base salary, a grant of a common stock, and health insurance coverage. Ms. Wilson was issued 500,000 shares of common stock of the Company in January 2014. In 2014, the Company paid compensation to Ms. Wilson totaling $157,582. In May 2013, the Company entered into the Shan Agreement and obtained exclusive rights to develop and commercialize the intellectual property developed and owned by Professor Shan as described in detail above under “Patent License Agreements.” In August 2014, Professor Shan executed an Assignment under which he transferred to the Company his entire right, title and interest in and to the licensed patents under the Shan Agreement and to CN 201210302259 Application of combination of LDN and MENK to preparation of anti-cancer drug for the consideration of 500,000 shares of our common stock. In April 2014, the Company entered into an agreement with Pixelheads, Inc. for the provision of public-company web services, maintenance and updates of its server infrastructure and technology, and website content management systems. Pixelheads, Inc. is owned by the son of Noreen Griffin, the Company’s Chief Executive Officer. The Company currently pays a monthly fee of $7,500 under the agreement.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent Events Between January 1, 2016 and March 30, 2016, the Company issued shares as follows: Number of Shares Issuance of common stock to employees and consultants, including employee settlement 16,493,000 Issuance of common stock for cash 312,500 Issuance of common stock in exchange for debt 8,349,425 As of March 21, 2016, the Company had outstanding 200,449,342 shares of common stock. Between January 1, 2016 and March 21, 2016, the Company issued 13,050,000 warrants for services and employment, exercisable into one share of common stock of the Company for each warrant at a price of $0.20 per share. The warrants expire between January 2021 and March 2021. The Company also issued 3,000,000 warrants to a contractor, exercisable into one share of common stock of the Company for each warrant, at prices between $0.50 and $2.00 per share. These warrants fully vest between October 1, 2016 and October 1, 2017, and expire between October 2019 and October 2020.

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Summary Of Significant Accounting Policies Policies
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with United States (U.S.) generally accepted accounting principles (U.S. GAAP) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented. The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue for the year ended December 31, 2014. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.
Revenue Recognition	Revenue Recognition Revenue from product sales is recognized upon passage of title and risk of loss to customers. Provisions for discounts, rebates and sales incentives to customers, and returns and other adjustments are provided for in the period the related sales are recorded. Historical data are not yet readily available and reliable for use in estimating the amount of the reduction in gross sales. Revenue from the launch of a new product, from an improved version of an existing product, or for shipments in excess of a customer’s normal requirements will be recorded when the conditions noted above are met. In those situations, management will record a returns reserve for such revenue, if necessary. If in future the Company participates in selling arrangements that include multiple deliverables (e.g., instruments, reagents, procedures, and service agreements), under these arrangements, the Company will recognize revenue upon delivery of the product or performance of the service and will allocate the revenue based on the relative selling price of each deliverable, which will be based primarily on vendor specific objective evidence. Revenue from license of product rights is recorded over the periods earned. In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers, which provides a single comprehensive model for accounting for revenue from contracts with customers and will supersede most existing revenue recognition guidance. Early adoption is not permitted. The standard becomes effective for the Company in the first quarter of 2017. The Company is currently evaluating the effect, if any, that the standard will have on its consolidated financial statements and related disclosures.
Use of Estimates	Use of Estimates The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.
Cash, Cash Equivalents, and Short-term Investments	Cash, Cash Equivalents, and Short-Term Investments The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $250,000. At December 31, 2015, the Company has no cash balances in excess of insured limits.
Segment and Geographic Information	Segment and Geographic Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and does not segment the business for internal reporting or decision making.
Fair Value of Financial Instruments	Fair Value of Financial Instruments In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “ Financial Instruments”
Fair Value Measurements	Fair Value Measurements The ASC Topic 820, Fair Value Measurement,
Property and Equipment	Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to five years. Maintenance and repairs are charged against expense as incurred. Depreciation expense from continuing operations for the years ended December 31, 2015 and December 31, 2014 was $2,552 and $2,485, respectively.
Intangible Assets	Intangible Assets Costs incurred to acquire and/or develop the Company’s product licenses and patents are capitalized and amortized by straight-line methods over estimated useful lives of ten to sixteen years. Intangible assets are stated at the lower of cost or estimated fair value. During the years ended December 31, 2015 and December 31, 2014, the Company capitalized $nil and $57,340 respectively, of such costs incurred for the Company’s acquisition of licenses for the patents. (See Note 10). Amortization expense for the years ended December 31, 2015 and December 31, 2014 was $592,233 and $2,876,826, respectively.
Impairment of Long-lived Assets	Impairment of Long-Lived Assets The Company evaluates long-lived assets for impairment whenever events or change in circumstances indicate that the carrying amount of an asset may not be recoverable as prescribed by ASC Topic 360-10-05, “ Property, Plant and Equipment
Research and Development Costs	Research and Development Costs Research and development costs are charged to expense as incurred and are typically comprised of salaries and benefits, pre-clinical studies, clinical trial activities, drug development and manufacturing, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf and third-party service fees, including clinical research organizations and investigative sites. Costs for certain development activities, such as clinical trials are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as operating expenses.
Income Taxes	Income Taxes The Company follows ASC Topic 740, Income Taxes, The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. At the date of adoption, and as of December 31, 2015, and 2014, the Company does not have a liability for unrecognized tax uncertainties. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of December 31, 2015, and 2014, the Company has not accrued any interest or penalties related to uncertain tax positions.
Stock-based Compensation and Issuance of Stock for Non-cash Consideration	Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors, including employee stock options, based on estimated fair values equaling either the market value of the shares issued or the value of consideration received, whichever is more readily determinable. The majority of the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair value of the Company’s common stock at the date of the agreement. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 505-50, “ Equity-Based Payments to Non-Employees
Non-controlling Interest	Non-controlling Interest In accordance with ASC Topic 810, Consolidation
Net Loss Per Share	Net Loss per Share Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. Dilutive common stock equivalents are comprised of common stock purchase warrants outstanding. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. A calculation of basic and diluted net loss per share follows: For the year ended December 31, 2015 2014 Historical net loss per share: Numerator Net loss $ (16,949,451 ) $ (49,938,213 ) Non-controlling interest (2,706,939 ) (1,684,996 ) Net loss attributed to Common stockholders $ (14,242,512 ) $ (48,253,217 ) Denominator Weighted-average common shares outstanding— Denominator for basic and diluted net loss per share 153,247,023 98,508,458 Basic and diluted net loss per share attributed to common stockholders $ (0.09 ) $ (0.49 ) The Company’s potential dilutive securities which include stock and warrants have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average Common stock outstanding used to calculate both basic and diluted net loss per share is the same. The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as the effect of including such securities would be antidilutive: Year Ended December 31, 2015 2014 Common Stock Purchase Warrants 9,131,500 9,296,750
Recent Accounting Standards	Recent Accounting Standards During the year ended December 31, 2015 and through March 30, 2016, there were several new accounting pronouncements issued by the Financial Accounting Standards Board. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial statements. The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue and did not have such amount as of December 31, 2015, our last fiscal year. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Summary Of Significant Accounting Policies Tables
Schedule of Basic and Diluted Net Loss Per Share	A calculation of basic and diluted net loss per share follows: For the year ended December 31, 2015 2014 Historical net loss per share: Numerator Net loss $ (16,949,451 ) $ (49,938,213 ) Non-controlling interest (2,706,939 ) (1,684,996 ) Net loss attributed to Common stockholders $ (14,242,512 ) $ (48,253,217 ) Denominator Weighted-average common shares outstanding— Denominator for basic and diluted net loss per share 153,247,023 98,508,458 Basic and diluted net loss per share attributed to common stockholders $ (0.09 ) $ (0.49 )
Schedule of Antidilutive Securities	The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as the effect of including such securities would be antidilutive: Year Ended December 31, 2015 2014 Common Stock Purchase Warrants 9,131,500 9,296,750

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2015
Property And Equipment Tables
Schedule of Property and Equipment	December 31, 2015 2014 Property and equipment: Computer equipment $ 8,013 $ 8,013 Less accumulated depreciation (6,331 ) (3,778 ) Property and equipment, net $ 1,682 $ 4,235

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2015
Accrued Liabilities Tables
Schedule of Accrued Liabilities	Accrued expenses and other liabilities consist of the following: December 31, 2015 2014 Retainer for legal services $ - $ 60,000 Accrued payroll to officers and others 758,342 762,633 Accrued interest - notes payable 236,671 1,808 Estimated legal settlement 282,136 278,681 Other accrued liabilities 323 6,933 State payroll taxes 3,567 1,784 Total accrued expenses and other liabilities $ 1,281,039 $ 1,111,839

Notes Payable (Tables)

Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Payable Tables
Schedule of Notes Payable	Notes payable consist of the following: December 31, 2015 December 31, 2014 Promissory note issued July 29, 2014 to Ira Gaines. The note matures on January 27, 2015 and earns interest at a rate of 18% per annum. The Company was unable to repay the note at maturity and the note is in default, although no demand for repayment has been made by the lender. $ 100,000 $ 100,000 Promissory notes issued between November 26, 2014 and September 30, 2015, to raise up to $2,000,000 in debt. Lenders earn interest at a rate of 10% per annum, plus a pro-rata share of two percent of the Company’s gross receipts for sales of IRT-103-LDN in perpetuity. Notes will be repaid in 36 monthly installments of principal and interest commencing no later than October 15, 2015. Notes aggregating $711,500 were in default at December 31, 2015, as the Company was unable to pay installments on those notes on their due dates. No demands for repayment have been made by the lenders. Subsequent to December 31, 2015, $380,500 of these notes and their accompanying interest were converted into 5,389,409 shares of Immune Therapeutics common stock. 711,500 406,525 Promissory note issued October 17, 2014 to Roger Bozarth. The note matures on October 17, 2015 and earns interest at a rate of 2% per annum. The Company was unable to repay the note at maturity and the note is in default, although no demand for repayment has been made by the lender. Subsequent to December 31, 2015, this note and the accompanying interest was converted into 89,639 shares of Immune Therapeutics common stock. 7,000 7,000 Promissory notes issued between May 1, 2015 and September 30, 2015, and maturing between June 14, 2015 and December 31, 2015. Lenders on loans aggregating $506,433 earn interest at rates between 10% and 18% per annum. On loans aggregating $98,500, interest is payable in a fixed amount not tied to a specific interest rate. Notes aggregating $669,933 were in default at December 31, 2015, as the Company was unable to repay those notes on their due dates. No demands for repayment have been made by the lenders. Subsequent to December 31, 2015, $135,000 of these notes and their accompanying interest were converted into 2,870,377 shares of Immune Therapeutics common stock. 669,933 - Promissory note issued January 26, 2015 to Robert J. Dailey. The note is senior to, and has priority in right of payment over, all indebtedness of the Company. The note earns interest at a rate of 2% per annum and was due on July 30, 2015. The Company was unable to repay the note at maturity and the note is in default, although no demand for repayment has been made by the lender. 200,000 - Promissory notes issued by Cytocom Inc. between April 29, 2015 and December 31, 2015. Lenders earn interest at rates between 5% and 10% per annum. These notes mature on September 30, 2016. 800,000 - Promissory notes issued in December 2015. Lenders earn interest at a rate of 10% per month. Notes are repayable on March 9, 2016. The Company was unable to repay the note at maturity and the note is in default. The Company is obligated to pay late-payment penalties totaling $6,667 per day. 130,000 - Promissory note issued November 24, 2015 as settlement of amounts owing to a law firm. The Lender earns interest at the rate of 10% per annum. The note is repayable in full on December 1, 2016. 175,268 - Total 2,793,701 513,525 Less: Current Portion (2,793,701 ) (186,067 ) Long-Term debt, less current portion $ - $ 327,458

Capital Structure - Common St24

Capital Structure - Common Stock and Common Stock Purchase Warrants (Tables)	12 Months Ended
	Dec. 31, 2015
Capital Structure - Common Stock And Common Stock Purchase Warrants Tables
Schedule of Outstanding Stock Warrants	Following is a summary of outstanding stock warrants at December 31, 2015 and 2014 and activity during the years then ended: Number of Shares Exercise Price Weighted Average Price Warrants as of December 31, 2014 9,396,750 $ 0.14-15 $ 1.72 Issued 435,000 $ 0.07-0.50 $ 0.40 Expired (676,250 ) $ 1.50 $ 1.50 Exercised (24,000 ) $ 0.50 $ 0.50 Warrants as of December 31, 2015 9,131,500 $ 0.07-15.00 $ 1.47
Summary of Outstanding Warrants	Summary of outstanding warrants as of December 31, 2015: Expiration Date Number of Shares Exercise Price Remaining Life (years) Second Quarter 2016 37,500 $ 5.00 .50 Third Quarter 2016 525,000 $ 1.00-5.00 .75 Third Quarter 2017 1,500,000 $ 1.00 1.75 Fourth Quarter 2017 2,941,666 $ 1.00-9.00 2.00 First Quarter 2018 127,500 $ 15.00 2.25 Second Quarter 2018 33,334 $ 15.00 2.50 Third Quarter 2018 650,000 $ 1.00-1.50 2.75 Fourth Quarter 2018 1,197,500 $ 1.00-1.50 3.00 First Quarter 2019 1,024,000 $ 1.50 3.25 Second Quarter 2019 135,000 $ 0.07–0.23 3.50 Third Quarter 2019 260,000 $ 0.50 3.75 Fourth Quarter 2019 400,000 $ 0.14 4.00 Second Quarter 2020 300,000 $ 0.50 4.50

Income Taxes - Results of Ope25

Income Taxes - Results of Operations (Tables)	12 Months Ended
	Dec. 31, 2015
Income Taxes - Results Of Operations Tables
Schedule of Deferred Tax Assets	Deferred tax assets: 2015 2014 Net operating losses $ 22,611,000 $ 20,710,000 Stock based compensation 60,914,000 59,032,000 Amortization, depreciation, and impairment 6,765,000 4,786,000 Capitalization of start-up costs for tax purposes 1,854,000 1,854,000 Loss on debt conversion of debt 502,000 502,000 Total deferred tax assets 92,646,000 86,884,000 Valuation allowance (92,646,000 ) (86,884,000 ) Total deferred tax assets, net $ - $ -
Schedule of Income Taxes NOL	As of December 31, 2015, we have estimated federal and state income tax net operating loss (“NOL”) carry-forwards of approximately $66,500,000, which will expire in 2032-2035. 2015 2014 Amount Percent Amount Percent Benefits for income tax at federal statutory rate $ 5,763,000 34 % $ 16,978,000 34 % Change in valuation allowance (5,762,000 ) (34 )% $ (16,973,000 ) (34 ) Permanent differences (1,000 ) - (5,000 ) - Non-deductible impairment of goodwill - - - - $ - - $ - - %

Subsequent Events (Tables)

Subsequent Events (Tables)	12 Months Ended
	Dec. 31, 2015
Subsequent Events Tables
Summary of Issued Shares	Between January 1, 2016 and March 30, 2016, the Company issued shares as follows: Number of Shares Issuance of common stock to employees and consultants, including employee settlement 16,493,000 Issuance of common stock for cash 312,500 Issuance of common stock in exchange for debt 8,349,425

Organization and Description 27

Organization and Description of Business (Details Narrative) - USD ($)	Dec. 08, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Net loss			$ (16,949,451)	$ (49,938,213)
Cash equivalents			2,832,213
Stockholders equity			$ (5,958,184)	$ 2,352,432	$ 16,631,247
Cytocom Inc., [Member]
Number of shares issued druing period	113,242,522		140,100,000
Percentage of stake issued during period	55.30%		50.20%
Irish Limited Liability [Member]
Percentage of low corporate income tax rate		12.50%

Summary of Significant Accoun28

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Summary Of Significant Accounting Policies Details Narrative
Maximum of annual gross revenue	$ 1,000,000,000	$ 1,000,000,000
Federal deposit insurance corporation value	250,000
Depreciation expense	$ 2,552	2,485
Intangible Assets cost capitalized and amortized		57,340
Amortization expense	$ 592,233	2,876,826
Impairment loss	$ 5,226,352	$ 9,908,477

Summary of Significant Accoun29

Summary of Significant Accounting Policies - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Summary Of Significant Accounting Policies - Schedule Of Basic And Diluted Net Loss Per Share Details
Numerator, Net loss	$ (16,949,451)	$ (49,938,213)
Numerator, Non-controlling interest	(2,706,939)	(1,684,996)
Numerator, Net loss attributed to Common stockholders	$ (14,242,512)	$ (48,253,217)
Denominator, Weighted-average common shares outstanding-Denominator for basic and diluted net loss per share	153,247,023	98,508,458
Denominator, Basic and diluted net loss per share attributed to common stockholders	$ (0.09)	$ (0.49)

Summary of Significant Accoun30

Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Summary Of Significant Accounting Policies - Schedule Of Basic And Diluted Net Loss Per Share Details
Common Stock Purchase Warrants	9,131,500	9,296,750

Property and Equipment (Details

Property and Equipment (Details Narrative)	12 Months Ended
	Dec. 31, 2015
Property And Equipment Details Narrative
Depreciable asset lives	5 years

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Property And Equipment - Schedule Of Property And Equipment Details
Computer equipment	$ 8,013	$ 8,013
Less accumulated depreciation	(6,331)	(3,778)
Property and equipment, net	$ 1,682	$ 4,235

Accrued Liabilities - Schedule

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Accrued Liabilities - Schedule Of Accrued Liabilities Details
Retainer for legal services		$ 60,000
Accrued payroll to officers and others	$ 758,342	762,633
Accrued interest - notes payable	236,671	1,808
Estimated legal settlement	282,136	278,681
Other accrued liabilities	323	6,933
State payroll taxes	3,567	1,784
Total accrued expenses and other liabilities	$ 1,281,039	$ 1,111,839

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Notes Payable Details Narrative
Accrued unpaid interest	$ 236,671	$ 1,808
Number of shares issued during period	62,500	670,000
Fair value of issued shares	$ 15,625	$ 302,450

Notes Payable - Schedule of Not

Notes Payable - Schedule of Notes Payable (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Total	$ 2,793,701	$ 513,525
Less: Current portion	$ (2,793,701)	(186,067)
Long-Term debt, less current portion		327,458
Notes Payable One [Member]
Total	$ 100,000	100,000
Notes Payable Two [Member]
Total	711,500	406,525
Notes Payable Three [Member]
Total	7,000	$ 7,000
Notes Payable Four [Member]
Total	669,933
Notes Payable Five [Member]
Total	200,000
Notes Payable Six [Member]
Total	800,000
Notes Payable Seven [Member]
Total	130,000
Notes Payable Eight [Member]
Total	$ 175,268

Notes Payable - Schedule of N36

Notes Payable - Schedule of Notes Payable (Details) (Parenthetical)	Nov. 24, 2015	Jan. 26, 2015	Oct. 17, 2014	Jul. 29, 2014	Dec. 31, 2015USD ($)	Mar. 31, 2015	Sep. 30, 2015USD ($)Installments	Dec. 31, 2015USD ($)shares	Dec. 31, 2014USD ($)shares
Percentage of interest rate per annum							10.00%
Maximum amount raise in debt							$ 2,000,000
Number of installments, months | Installments							36
Value of notes that converted into shares								$ 15,625	$ 302,450
Notes and interest converted into shares | shares								62,500	670,000
Cytocom Inc., [Member]
Note matures date						Sep. 30, 2016
Minimum [Member] | Cytocom Inc., [Member]
Percentage of interest rate per annum					5.00%			5.00%
Maximum [Member] | Cytocom Inc., [Member]
Percentage of interest rate per annum					10.00%			10.00%
Ira Gaines [Member]
Note matures date				Jan. 27, 2015
Percentage of interest rate per annum				18.00%
Lenders [Member]
Notes aggregating default amount					$ 711,500			$ 711,500
Value of notes that converted into shares								$ 380,500
Notes and interest converted into shares | shares								5,389,409
Aggregating loan							$ 506,433
Interest payable							$ 98,500
Lenders [Member] | Minimum [Member]
Percentage of interest rate per annum							10.00%
Lenders [Member] | Maximum [Member]
Percentage of interest rate per annum							18.00%
Roger Bozarth [Member]
Note matures date			Oct. 17, 2015
Percentage of interest rate per annum			2.00%
Notes and interest converted into shares | shares								89,639
Lenders [Member]
Maximum amount raise in debt					135,000			$ 135,000
Notes aggregating default amount					$ 669,933			$ 669,933
Notes and interest converted into shares | shares								2,870,377
Robert J. Dailey [Member]
Note matures date		Jul. 30, 2015
Percentage of interest rate per annum		2.00%
Lender [Member]
Note matures date					Mar. 9, 2016
Percentage of interest rate per annum					10.00%			10.00%
Pay late-payment penalties per day					$ 6,667			$ 6,667
Lender [Member]
Note matures date	Dec. 1, 2016
Percentage of interest rate per annum	10.00%

Capital Structure - Common St37

Capital Structure - Common Stock and Common Stock Purchase Warrants (Details Narrative) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Common Stock, Par Value	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	500,000,000	500,000,000
Common Stock, Shares Issued	174,850,047	134,417,210
Common Stock, Shares Outstanding	174,850,047	134,417,210
Number of warrants issued during period	435,000
Warrant expire term	expire between Jan 2016 and Dec 2021.
Minimum [Member]
Warrant price per share	$ 0.07
Maximum [Member]
Warrant price per share	$ 0.50

Capital Structure - Common St38

Capital Structure - Common Stock and Common Stock Purchase Warrants - Schedule of Outstanding Stock Warrants (Details) - Warrant [Member]	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Warrants, Number of shares Beginning balance | shares	9,396,750
Warrants, Number of shares Issued | shares	435,000
Warrants, Number of shares Expired | shares	(676,250)
Warrants, Number of shares Exercised | shares	(24,000)
Warrants, Number of shares Ending balance | shares	9,131,500
Exercise Price, Expired	$ 1.50
Exercise Price, Exercised	.50
Weighted average exercise price, Beginning balance	1.72
Weighted average exercise price, Issued	0.40
Weighted average exercise price, Expired	1.50
Weighted average exercise price, Exercised	.50
Weighted average exercise price, Ending balance	1.47
Minimum [Member]
Exercise Price, Beginning balance	0.14
Exercise Price, Issued	0.07
Exercise Price, Ending balance	0.07
Maximum [Member]
Exercise Price, Beginning balance	15
Exercise Price, Issued	.50
Exercise Price, Ending balance	$ 15

Capital Structure - Common St39

Capital Structure - Common Stock and Common Stock Purchase Warrants - Summary of Outstanding Warrants (Details)	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Second Quarter 2016 [Member]
Number of Shares | shares	37,500
Exercise Price Lower Limit	$ 5
Remaining Life (years)	6 months
Third Quarter 2016 [Member]
Number of Shares | shares	525,000
Exercise Price Lower Limit	$ 1
Exercise Price Upper Limit	$ 5
Remaining Life (years)	9 months
Third Quarter 2017 [Member]
Number of Shares | shares	1,500,000
Exercise Price Lower Limit	$ 1
Remaining Life (years)	1 year 9 months
Fourth Quarter 2017 [Member]
Number of Shares | shares	2,941,666
Exercise Price Lower Limit	$ 1
Exercise Price Upper Limit	$ 9
Remaining Life (years)	2 years
First Quarter 2018 [Member]
Number of Shares | shares	127,500
Exercise Price Lower Limit	$ 15
Remaining Life (years)	2 years 3 months
Second Quarter 2018 [Member]
Number of Shares | shares	33,334
Exercise Price Lower Limit	$ 15
Remaining Life (years)	2 years 6 months
Third Quarter 2018 [Member]
Number of Shares | shares	650,000
Exercise Price Lower Limit	$ 1
Exercise Price Upper Limit	$ 1.50
Remaining Life (years)	2 years 9 months
Fourth Quarter 2018 [Member]
Number of Shares | shares	1,197,500
Exercise Price Lower Limit	$ 1
Exercise Price Upper Limit	$ 1.50
Remaining Life (years)	3 years
First Quarter 2019 [Member]
Number of Shares | shares	1,024,000
Exercise Price Lower Limit	$ 1.50
Remaining Life (years)	3 years 3 months
Second Quarter 2019 [Member]
Number of Shares | shares	135,000
Exercise Price Lower Limit	$ 0.07
Exercise Price Upper Limit	$ 0.23
Remaining Life (years)	3 years 6 months
Third Quarter 2019 [Member]
Number of Shares | shares	260,000
Exercise Price Lower Limit	$ .50
Remaining Life (years)	3 years 9 months
Fourth Quarter 2019 [Member]
Number of Shares | shares	400,000
Exercise Price Lower Limit	$ .14
Remaining Life (years)	4 years
Second Quarter 2020 [Member]
Number of Shares | shares	300,000
Exercise Price Lower Limit	$ .50
Remaining Life (years)	4 years 6 months

Stock Compensation (Details Nar

Stock Compensation (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Number of common stock issued for consulting fees	16,672,504	17,178,294
Amortization of prepaid services	$ 4,328,768	$ 22,855,925
Minimum [Member]
Consulting fees amortized period	12 months
Maximum [Member]
Consulting fees amortized period	24 months

Income Taxes - Results of Ope41

Income Taxes - Results of Operations (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Taxes - Results Of Operations Details Narrative
Effective tax rate	0.00%	0.00%
Deferred tax assets
Operating loss carryforwards		$ 66,500,000
Operating loss carryforwards expire term	expire in 2032-2035.

Income Taxes - Results of Ope42

Income Taxes - Results of Operations - Schedule of Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Income Taxes - Results Of Operations - Schedule Of Deferred Tax Assets Details
Net operating losses	$ 22,611,000	$ 20,710,000
Stock based compensation	60,914,000	59,032,000
Amortization, depreciation, and impairment	6,765,000	4,786,000
Capitalization of start-up costs for tax purposes	1,854,000	1,854,000
Loss on debt conversion of debt	502,000	502,000
Total deferred tax assets	92,646,000	86,884,000
Valuation allowance	$ (92,646,000)	$ (86,884,000)
Total deferred tax assets, net

Income Taxes - Results of Ope43

Income Taxes - Results of Operations - Schedule of Income Taxes NOL (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Taxes - Results Of Operations - Schedule Of Deferred Tax Assets Details
Benefits for income tax at federal statutory rate	$ 5,763,000	$ 16,978,000
Change in valuation allowance	(5,762,000)	(16,973,000)
Permanent differences	$ (1,000)	$ (5,000)
Non-deductible impairment of goodwill
NOL
Benefits for income tax at federal statutory rate, percent	34.00%	34.00%
Change in valuation allowance, percent	(34.00%)	(34.00%)
Permanent differences, percent
Non-deductible impairment of goodwill, percent
NOL, percent

Licenses and Supply Agreements

Licenses and Supply Agreements (Details Narrative) - USD ($)	Sep. 24, 2014	Aug. 06, 2014	Dec. 24, 2012	Aug. 13, 2012	Apr. 24, 2012	May. 31, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Issued common stock value							$ 1,831,376	$ (897,500)
Young Agreement [Member]
Patent liability									$ 118,333
Cost of the patent									$ 1,372,000
Smith Agreement [Member]
Number of shares acquired in exchange for common stock			300,000
Acquisition value			$ 2,880,384
Fair market value acquired			2,715,000
Payments for expenses			165,384
Number of common stock shares issued during period	1,000,000
Issued common stock value	$ 270,000
Smith Agreement [Member] | Initial License Fee [Member]
Payments for expenses			100,000
Smith Agreement [Member] | Expenses [Member]
Payments for expenses			$ 65,384
Shan Agreement [Member]
Number of common stock shares issued during period		500,000
Issued common stock value		$ 140,000
Number of shares issue upon final transfer of licenses						500,000
Dr. Plotnikoff [Member]
Number of shares acquired in exchange for common stock					8,000,000
TNI IP’s Management [Member]
Number of shares acquired in exchange for common stock					12,250,000
Acquisition value					$ 16,006,000
Dr. Bernard Bihari [Member] | Young Agreement [Member]
Number of shares acquired in exchange for common stock				540,000
Acquisition value				$ 972,000
Assumed liabilities				$ 400,000
TNI BioTech IP, Inc. [Member]
Number of shares acquired in exchange for common stock					20,250,000
Acquisition value					$ 98,000,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)

Oct. 24, 2015USD ($)

Nov. 09, 2012USD ($)Dose$ / shares

Oct. 18, 2012

Sep. 25, 2012USD ($)

Jul. 14, 2012USD ($)

Sep. 30, 2015USD ($)

Oct. 31, 2014USD ($)

Feb. 28, 2014USD ($)

Oct. 30, 2013

Oct. 31, 2015USD ($)

Dec. 31, 2015USD ($)

Dec. 31, 2014USD ($)

Letter of intent, description

the letter of intent, the Company and GBOIG intend to provide HIV/AIDS treatment to 25,000 patients and hopefully expanding to 500,000 within 24 months.

Initial capital to venture

$ 1,000

Percentage of allocated income from venture

50.00%

Cash rental expense

$ 53,205

$ 147,236

Promissory note

$ 327,458

Bearing an interest rate

10.00%

Plaintiff Claims [Member]

Seeking damages in excess

$ 194,000

$ 75,000

Default judgment entered in favor of legal party amount

$ 19,474

$ 80,000

Accrued for claim

$ 210,452

Withdrew from bank account towards settlement of claim

$ 92,590

Promissory note

$ 175,267

Bearing an interest rate

10.00%

Ballon payment amount

$ 192,794

Plaintiff EK Krause & Associates [Member]

Default judgment entered in favor of legal party amount

259,894

Accrued for claim

$ 279,000

GBOIG [Member]

Upfornt costs

$ 2,500,000

Distribution Agreements In Nigeria [Member]

Upfornt costs

Revolving letter of credit minimum puchase dose | Dose

750,000

Price per dose | $ / shares

$ 1

Distribution Agreement, description

The Distribution Agreement calls for G-Ex Technologies/St. Maris Pharma and GB Pharma Holdings, LLC to purchase a minimum of 15,000,000 doses monthly within 24 months to maintain the exclusivity of the agreement. Once G-Ex Technologies/St. Maris Pharma and GB Pharma Holdings, LLC reach sales of 1,000,000 doses per day, we have agreed to joint venture a factory in the Federal Republic of Nigeria to meet local demands.

AHAR Pharma [Member]

Distribution Agreement, description

the Company is obligated to provide delivery of an initial supply of between 1 million and 1.5 million doses of Lodonal™ product to cover AHAR Pharma’s first-year purchase commitment.

Agreements With Hubei Qianjiang Pharmaceutical Company [Member]

Percentage of gross sales

6.00%

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Sep. 30, 2014	Jan. 03, 2013	Apr. 30, 2014	May. 31, 2013	Sep. 30, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2012
Number of shares issued during period						62,500	670,000
Fair value of issued shares						$ 15,625	$ 302,450
Shan Agreement [Member]
Number of shares issued during period				500,000
Webfoot, Inc [Member]
Loan amount	$ 71,128				$ 71,128			$ 121,128
Repaid loan					40,000
Accrued and unpaid interest	10,212				$ 10,212
Number of shares issued during period					813,404
Fair value of issued shares					$ 162,681
Noreen Griffin [Member]
Repaid loan								30,000
Accrued and unpaid interest	$ 2,870				2,870
Number of shares issued during period	328,701
Merger-related expenses								46,000
Loss on conversion	$ 65,740
Griffin Enterprises, Inc [Member]
Loan amount								$ 46,000
Accrued and unpaid interest	$ 4,401				$ 4,401
Number of shares issued during period	504,009
Loss on conversion	$ 100,802
Ms. Wilson [Member]
Number of shares issued during period		500,000
Paid compensation							$ 157,582
Pixelheads, Inc. [Member]
Pays monthly fee			7,500

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 21, 2016	Dec. 31, 2015	Dec. 31, 2014
Common Stock, Shares Outstanding		174,850,047	134,417,210
Warrant expire term		expire between Jan 2016 and Dec 2021.
Minimum [Member]
Warrant price per share		$ 0.07
Maximum [Member]
Warrant price per share		$ 0.50
Subsequent Event [Member]
Common Stock, Shares Outstanding	200,449,342
Number of warrant issued for services and employment	13,050,000
Warrant price per share	$ .20
Warrant expire term	January 2021 and March 2021.
Subsequent Event [Member] | Minimum [Member]
Warrant price per share	$ .50
Subsequent Event [Member] | Maximum [Member]
Warrant price per share	$ 2
Subsequent Event [Member] | Contractor [Member]
Number of warrant issued for services and employment	3,000,000
Warrant expire term	October 2019 and October 2020.
Warrant vest term	October 1, 2016 and October 1, 2017

Subsequent Events - Summary of

Subsequent Events - Summary of Issued Shares (Details) - Subsequent Event [Member]	3 Months Ended
	Mar. 21, 2016shares
Issuance of common stock to employees and consultants, including employee settlement	16,493,000
Issuance of common stock for cash	312,500
Issuance of common stock in exchange for debt	8,349,425